Kyverna Therapeutics, Inc.
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA).
KYV-101 continues to demonstrate a well-tolerated profile, consistent with observations from 100 patients treated with KYV-101 to date.
Emerging IIT data in RA reinforce broad potential for KYV-101 in rheumatology indications.
Author summary: Kyverna presents promising data on KYV-101.
More News
- 2 US Navy aircraft crash in South China Sea
- 5 members of the 2025 Yankees make list of top 50 free agents
- Lorin Gutierrez reveals best beauty advice from mom Ruffa, lola Annabelle
- The environmental impact of the 2026 World Cup
- Sweden’s still ahead in the preparedness game — and now it means business
- Budget jitters see construction forecasts plummet
- West Indies ease past Bangladesh in first T20I
- Three resilient UK multinationals global managers are excited about | Trustnet
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- Zorin OS Breaks Download Record as Windows 10 Users Seek Alternatives